Adding angiotensin II receptor blockers (ARBs) to conventional therapy for lupus nephritis significantly reduces proteinuria, according to a report presented here Sunday at the American College of Rheumatology (ACR) 66th Annual Scientific Meeting.
About half of patients with systemic lupus erythematosus (SLE) acquire lupus nephritis, note principal investigator Toshihide Mimura, MD, PhD, chief of the division of rheumatology at Saitama Medical School, Japan, and colleagues. However, while steroids and immunosuppressive agents are useful, some patients remain refractory to these drugs.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!